Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
2.160
-0.190 (-8.09%)
At close: Apr 1, 2025, 4:00 PM
2.273
+0.113 (5.22%)
After-hours: Apr 1, 2025, 4:18 PM EDT

Company Description

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases.

Its investigational product, certepetide, is in Phase 2 clinical studies for the treatment of solid tumor, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, colon cancer and glioblastoma multiforme, in combination with a range of anti-cancer regimens.

Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Lisata Therapeutics, Inc.
Lisata Therapeutics logo
Country United States
Founded 1980
Industry Biotechnology
Sector Healthcare
Employees 26
CEO David Mazzo

Contact Details

Address:
110 Allen Road, 2nd Floor
Basking Ridge, New Jersey 07920
United States
Phone 908 842 0100
Website lisata.com

Stock Details

Ticker Symbol LSTA
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000320017
CUSIP Number 128058302
ISIN Number US1280583022
Employer ID 22-2343568
SIC Code 2834

Key Executives

Name Position
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. President, Chief Executive Officer and Director
Dr. Kristen K. Buck M.D. Executive Vice President of Research & Development and Chief Medical Officer
James Nisco Senior Vice President of Finance, Treasurer, CAO and Principal Financial and Accounting Officer
Tariq Imam Senior Vice President of Business Development and Operations and General Counsel
Gregory S. Berkin Chief Information and Data Protection Officer
John D. Menditto Vice President of Investor Relations and Corporate Communications
Gail Holler Vice President of Human Resources
Dr. William K. Sietsema Ph.D. Vice President of Global Regulatory Affairs

Latest SEC Filings

Date Type Title
Feb 27, 2025 10-K Annual Report
Feb 27, 2025 8-K Current Report
Jan 23, 2025 8-K Current Report
Dec 3, 2024 8-K Current Report
Nov 12, 2024 10-Q Quarterly Report
Nov 12, 2024 8-K Current Report
Aug 21, 2024 424B5 Filing
Aug 12, 2024 10-Q Quarterly Report
Aug 12, 2024 8-K Current Report
Jul 15, 2024 S-8 Securities to be offered to employees in employee benefit plans